GlassScriptPhysician profile
Suguna Chirla
NPI 1124105176
$4,178.25
in general payments reported to CMS, 2019-2025
42 companies · $99.09 in 2025
The $99.09 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $963 · 2020: $1,697 · 2021: $319 · 2022: $484 · 2023: $394 · 2024: $223 · 2025: $99.09.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $716.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $716.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Puma Biotechnology, INC. | $652.84 | 2019-2020 | |
| Pharmacyclics LLC, An Abbvie Company | $390.38 | 2019-2023 | Imbruvica |
| Astellas Pharma US INC | $285.67 | 2019-2023 | Padcev |
| Astrazeneca Pharmaceuticals LP | $270.82 | 2019-2024 | Tagrisso, Imfinzi |
| Pfizer INC. | $243.14 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $196.32 | 2019-2025 | Keytruda |
| Amgen INC. | $154.88 | 2019-2023 | Lumakras |
| Celgene Corporation | $154.15 | 2019-2023 | Reblozyl |
| Janssen Biotech, INC. | $145.03 | 2019-2021 | |
| Daiichi Sankyo INC. | $142.41 | 2020-2024 | Enhertu |
| E.R. Squibb & Sons, L.L.C. | $136.76 | 2019-2023 | Opdivo |
| Seagen INC. | $116.12 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $114.99 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $88.87 | 2019-2024 | |
| Eisai INC. | $80.05 | 2019-2024 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suguna Chirla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.